Evolus Inc (NASDAQ:EOLS), a medical aesthetics company, reported financial results for the fourth quarter and full year of 2025, delivering revenue growth but presenting a mixed earnings picture against analyst expectations. The company's stock showed modest positive movement in after-hours trading following the announcement.
Earnings and Revenue Versus Estimates
For the critical fourth quarter, Evolus posted results that narrowly missed on the top line but exceeded bottom-line expectations.
- Revenue: The company reported total net revenues of $90.3 million for Q4 2025. This represents a 14% increase year-over-year but came in slightly below the analyst consensus estimate of approximately $91.5 million.
- Earnings Per Share (Non-GAAP): Evolus reported non-GAAP income from operations of $7.1 million. On a per-share basis, the company reported non-GAAP EPS of $0.06, which surpassed the analyst estimate of $0.051.
The full-year 2025 results underscored the company's consistent growth trajectory, with total net revenues reaching $297.2 million, marking a 12% increase over 2024 and representing the company's sixth consecutive year of double-digit growth.
Market Reaction and Price Action
The market's initial reaction to the earnings report was cautiously positive. Following the release, the stock traded higher in after-hours activity. This suggests investors may be focusing on the earnings beat and the company's forward guidance rather than the slight revenue miss. This positive after-hours move contrasts with the stock's recent performance, which has seen declines over the past month.
Key Highlights from the Earnings Report
Beyond the headline numbers, management emphasized several operational and strategic milestones:
- Path to Profitability: The company highlighted achieving "profitability" in the fourth quarter, as defined by positive non-GAAP operating income. This was attributed to expense management actions taken earlier in the year. Looking ahead, Evolus expects to achieve sustainable profitability beginning in 2026.
- Portfolio and Customer Growth: The launch of its Evolysse™ line of hyaluronic acid fillers in the U.S. is gaining traction, with over 3,000 accounts having purchased the product. The company's flagship neurotoxin, Jeuveau®, continues to drive the bulk of revenue. Key performance indicators, such as customer reorder rates of approximately 71% and growth in its consumer loyalty program to nearly 1.4 million members, point to strong customer retention and engagement.
- 2026 Financial Outlook: Management provided guidance for the coming year that aligns closely with existing analyst expectations.
- The company projects 2026 total net revenues between $327 million and $337 million, implying 10% to 13% growth. This range brackets the current analyst sales estimate of approximately $336.8 million.
- For the first quarter of 2026, the company's implied trajectory appears consistent with the analyst revenue estimate of $74.0 million.
- Long-Term Targets: Evolus introduced a long-term financial outlook for 2028, targeting total net revenue between $450 million and $500 million and adjusted EBITDA margins of 13% to 15%.
Balance Sheet and Expenses
The company ended the year with $53.8 million in cash and cash equivalents. Notably, non-GAAP operating expenses for the second half of 2025 declined by 4% compared to the first half, reflecting the impact of cost-reduction measures. For 2026, Evolus expects non-GAAP operating expenses to grow only modestly (0% to 3%), aiming to expand operating leverage as revenue increases.
For a detailed breakdown of future earnings estimates and historical performance, you can review the Evolus earnings and estimates page here.
Disclaimer: This article is for informational purposes only and does not constitute financial advice, nor does it recommend any investment action. Investors should conduct their own research and consult with a qualified financial advisor before making any investment decisions.
